LPC-DHA inhibits Srebp activity and de novo lipogenesis and Mfsd2a is regulated by Srebp. by Jia Pei Chan (5593388)

“…Capital letters above each lane represent biological replicates for each genotype (<i>n</i> = 5 for NSC^WT and NSC^KO). (B) Western blot analysis of Scd1 and Mfsd2a expression in of NSC^WT and NSC^KO treated with or without 50 μM LPC-DHA or 50 μM DHA. …”

Interactomes of HMR/LHR interactors provide evidence for the existence of a defined HMR protein complex (related to Fig 1). by Andrea Lukacs (3752956)

Performance of the model with the inhibitory V0_D pathways removed. by Yaroslav I. Molkov (542831)

“…Decreasing <i>α</i> causes two bifurcations: (i) transition from symmetric alternations of flexor activity, i.e. with a phase difference of Δ<i>φ</i> = 0.5, to alternations with a phase difference of Δ<i>φ</i> ≠0.5 at X₇ and then (ii) from alternation to synchronization of flexor activity at X₆. …”

Pig growth over the course of the experiment. by James H. Bishop (2182486)

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants by Kalpana Dommaraju (650755)

“…The paucity of CD8 T cell responses identified following RV144 vaccination, with no evidence for V2 specificity, considered together both with the association of decreased infection risk in RV 144 participants with V-specific antibody responses and a V2 sieve effect, lead us to hypothesize that this sieve effect was not T cell specific. …”

Data_Sheet_2_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

“…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”

Data_Sheet_1_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

“…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”

Data_Sheet_3_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

“…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”

Data_Sheet_4_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

“…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”

microRNA-34a-Mediated Down-Regulation of the Microglial-Enriched Triggering Receptor and Phagocytosis-Sensor TREM2 in Age-Related Macular Degeneration - Fig 6 by Surjyadipta Bhattacharjee (3181674)

“…After vacuum evaporation of HFIP, aliquoted peptide was re-suspended with DMSO to 5 mM and diluted to 5 μM into the cell culture media; <b>(B)</b> cells were treated with a scrambled miRNA-34a sequence (miRNA-34a-<b>sc</b>; 30 nM;, control, <b>a-d</b>, middle row); or <b>(C)</b> with an LNA-stabilized miRNA-34a (30 nM; miRNA-34a stressed; <b>a-d</b>; bottom row); treatments were for 24 hr before incubation with 5 uM of Aβ42 (made up as in [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0150211#pone.0150211.ref033" target="_blank">33</a>]) for another 24 hr before assay; MG cells were subsequently stained using a murine amyloid beta MABN10 (red fluorescence λ_max~650 nm; anti-Aβ antibody, clone W0-2; Millipore, Bellerica MA), a TREM-2 antibody (M-227): sc-48765 (green fluorescence; λ_max~510 nm; Santa Cruz, Santa Cruz CA) or DAPI nuclear stain (blue fluorescence; λ_max~470 nm) as in <b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0150211#pone.0150211.g003" target="_blank">Fig 3</a>;</b> arrows indicate Aβ42 uptake into MG cells; note decreased presence of TREM2 in miRNA-34a treated MG cells (bottom row, panel B) and decrease in ingested Aβ42 peptide within C8B4 cells (<b>C</b>; bottom row, panel <b>d</b>). …”

Changes after 45 minutes in the proportion of LTP, LTD or no plasticity responses observed in L5PyNs population induced by the HFS protocol in the presence of D1R agonist or antago... by Claire Nicole Jeanne Meunier (703124)

“…<p>(A and D) Percentages of L5PyNs displaying LTP, LTD or no plasticity in 129/Sv mice and 5-HT_1AR-KO mice in control conditions. …”

Exemplar display during target selection. by Joshua B. Moskowitz (8506380)

HCWs participating in surveys. by A. H. Ayesha Lavell (16734002)

Expressed doubts about continuing career in hospital health care. by A. H. Ayesha Lavell (16734002)

Mean scores and standard deviations per survey according to subcategories. by A. H. Ayesha Lavell (16734002)

Expressed doubts about continuing career in hospital health care. by A. H. Ayesha Lavell (16734002)

Changes in depression, anxiety and PTSD symptoms according to baseline severity. by A. H. Ayesha Lavell (16734002)

Mean scores and 95% CI of mental health symptoms, COVID-19 admissions and effect size during follow-up. by A. H. Ayesha Lavell (16734002)

Baseline characteristics. by A. H. Ayesha Lavell (16734002)

“…In this longitudinal cohort study, HCWs received five surveys from November 2020 to March 2023 assessing self-reported symptoms of depression (PHQ-9), anxiety (GAD-7), PTSD (PCL-5), stress (PSS), burn-out (UBOS-EE), insomnia (ISI), resilience (RS) and work engagement (UWES). …”

HCWs with symptoms of depression, anxiety or PTSDs categorized by clinical cut-off scores. by A. H. Ayesha Lavell (16734002)